Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: suzetrigine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

NCT05455502
View directory record Official record
Conditions
Pain
Interventions
VX-548
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 22, 2026, 8:24 AM EDT
Enrolling by invitation Phase 4 Interventional

Suzetrigine vs Norco-postoperative Mohs Pain

NCT07575230
View directory record Official record
Conditions
Cutaneous Tumors, Mohs Micrographic Surgery
Interventions
Norco 5Mg-325Mg Tablet, Suzetrigine
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 2 Interventional

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

NCT06774625
View directory record Official record
Conditions
Acute Pain, Postoperative
Interventions
LTG-001 High Dose, LTG-001 Mid Dose, LTG-001 Low Dose, Placebo, Suzetrigine
Drug · Other
Lead sponsor
Latigo Biotherapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

NCT05661734
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
14
States / cities
Anaheim, California • Bakersfield, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 22, 2026, 8:24 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Suzetrigine Following Urogynecologic Surgery: Investigation of Postoperative Pain Management

NCT07856654
View directory record Official record
Conditions
Pelvic Organ Prolapse (POP), Postoperative Pain, Urogynecology
Interventions
Suzetrigine, Placebo
Drug
Lead sponsor
Aditi Talkad
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Recruiting Phase 3 Interventional

Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen

NCT07525219
View directory record Official record
Conditions
Analgesic Efficacy
Interventions
Suzetrigine, acetaminophen
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Not yet recruiting Phase 4 Interventional

Suzetrigine Versus Standard Analgesia After Skin Cancer Surgery

NCT07843134
View directory record Official record
Conditions
Postoperative Pain, Acute Pain, Skin Cancer, Cutaneous Malignancy, Mohs Surgery
Interventions
Suzetrigine, Acetaminophen Plus Ibuprofen
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
3
States / cities
Maple Grove, Minnesota • Minneapolis, Minnesota • Wyoming, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

NCT05034952
View directory record Official record
Conditions
Acute Pain
Interventions
VX-548, HB/APAP, Placebo (matched to VX-548), Placebo (matched to HB/APAP)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
7
States / cities
Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

NCT06820307
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, DRSP/EE, NGM/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

NCT06336096
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

NCT05541471
View directory record Official record
Conditions
Pain
Interventions
VX-548, Midazolam, Digoxin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

NCT05818852
View directory record Official record
Conditions
Pain
Interventions
VX-548, Moxifloxacin, Moxifloxacin Placebo, VX-548 Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants

NCT07378865
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Enrolling by invitation Phase 4 Interventional

Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures

NCT07145346
View directory record Official record
Conditions
Rib Fractures
Interventions
Suzetrigine (SUZ), Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 4 Interventional

A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

NCT06887972
View directory record Official record
Conditions
Acute Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Bellaire, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 4 Interventional

A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine

NCT07257133
View directory record Official record
Conditions
Post Operative Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

NCT05660538
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Suzetrigine, Pregabalin, Placebo (matched to SUZ), Placebo (matched to pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
50
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 22, 2026, 8:24 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Suzetrigine in Total Hip Arthroplasty

NCT07226700
View directory record Official record
Conditions
Total Hip Arthroplasty (THA), Total Hip Arthroplasty \(THA\), Total Hip Replacement, Total Hip Replacement Surgery, Total Hip Replacements, Total Hip Replacement Arthroplasty, Suzetrigine, Pain Management, Pain, Nav 1.8, JOURNAVX, Opioid Cessation, Opioid Consumption, Postoperative, Multimodal Analgesia, Randomized Controlled Trial, Randomized Controlled Study, Randomized Controlled Trials
Interventions
Suzetrigine, Placebo
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Not yet recruiting Phase 4 Interventional

Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty

NCT07624526
View directory record Official record
Conditions
Knee Arthritis, Knee Osteoarthritis
Interventions
Suzetrigine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants

NCT07570069
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, Efavirenz
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Not yet recruiting Phase 4 Interventional

Suzetrigine in Tonsillectomy for Opioid-sparing Pain Management

NCT07821931
View directory record Official record
Conditions
Tonsillectomy, Pharyngoplasty, Suzetrigine, Opioid, Postoperative Pain, Acute Pain
Interventions
Suzetrigine, Acetaminophen, oxycodone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Journavx to Treat Pain After Thumb Basal Joint Arthroplasty

NCT07723352
View directory record Official record
Conditions
Thumb Basal Joint Osteoarthritis, Postoperative Pain, Joint Replacement Surgery, Joint Replacement
Interventions
suzetrigine 100mg, Acetaminophen
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
40 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Recruiting Phase 4 Interventional

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

NCT07672015
View directory record Official record
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

NCT06696443
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
65
States / cities
Anniston, Alabama • Daphne, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 8:24 AM EDT